Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-Related Outcomes in Hospital and Primary Care Settings: A Retrospective Cohort Study in Infants in Catalonia (Spain)

• 2024

  Sign in to bookmark this resource.

  Sign in
• Ermengol Coma; Montserrat Martinez-Marcos; Eduardo Hermosilla; Jacobo Mendioroz; Anna Reñé; Francesc Fina
PMID: 38857952DOI: https://dx.doi.org/10.1136/archdischild-2024-327153

---

Access Resources

• Journal ArticleEN

About

This study in Catalonia, Spain analyzed the effectiveness of nirsevimab, a monoclonal antibody for RSV, in infants under 6 months old. The study showed significant reductions in hospital and ICU admissions for RSV-related conditions after nirsevimab administration, providing important insights for public health strategies.

---

Tags

Hazard: Infectious Disease

Audiences: Nurses; Physicians; Public Health Professionals

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Niresivemab Library

Keywords: Antiviral Agents; Bronchiolitis; Hospitalization; Infant; Infant, Newborn; Intensive Care Units; Respiratory Syncytial Virus Infections; Spain; Antibodies, Monoclonal, Humanized

Institutions: Institut Catala de la Salut; Generalitat de Catalunya; University of Barcelona

---

More like this

Evaluation of Antibody-Based Preventive Alternatives for Respiratory Syncytial Virus: A Novel Multi-Criteria Decision Analysis Framework and Assessment of Nirsevimab in Spain 2024 · University Carlos III, BioMad, Fisabio-Public Health, Catholic University of Valencia, Instituto de Salud Carlos III, Weber Foundation Outpatient Respiratory Syncytial Virus Infections and Novel Preventive Interventions 2024 · University Medical Center Utrecht, Respiratory Syncytial Virus NETwork (ReSViNET) Foundation Assessment of Effectiveness and Impact of Universal Prophylaxis With Nirsevimab for Prevention of Hospitalizations Due to Respiratory Syncytial Virus in Infants. The NIRSE-GAL Study Protocol 2024 · Instituto de Investigación Sanitaria, World Health Organization (WHO), University of Santiago de Compostela, Instituto de Salud Carlos III

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---